"Tandem" high-dose chemoradiotherapy with autologous stem-cell support in the treatment of newly diagnosed or responsive multiple myeloma.
D054598:Blue Cross Blue Shield Insurance Plans; D002469:Cell Separation / Q000295:instrumentation; D017024:Chemotherapy, Adjuvant; D018795:Device Approval; D017277:Drug Approval; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000532:radiotherapy*; D017063:Outcome Assessment, Health Care; D018714:Radiotherapy, Adjuvant; D013673:Technology Assessment, Biomedical; D014182:Transplantation, Autologous; D014481:United States; D014486:United States Food and Drug Administration